Non-alcoholic fatty liver disease: Insights into pathogenesis, molecular mechanisms, and therapy
Kamar, N., Michel, H., Seif el-Din, S., Lakkany, N., Elsherbiny, D. (2024). Non-alcoholic fatty liver disease: Insights into pathogenesis, molecular mechanisms, and therapy. EKB Journal Management System, 8(2), 245-260. doi: 10.21608/aps.2024.291298.1173
Nourhan M. Kamar; Haidy E. Michel; Sayed H. Seif el-Din; Naglaa M. Lakkany; Doaa A. Elsherbiny. "Non-alcoholic fatty liver disease: Insights into pathogenesis, molecular mechanisms, and therapy". EKB Journal Management System, 8, 2, 2024, 245-260. doi: 10.21608/aps.2024.291298.1173
Kamar, N., Michel, H., Seif el-Din, S., Lakkany, N., Elsherbiny, D. (2024). 'Non-alcoholic fatty liver disease: Insights into pathogenesis, molecular mechanisms, and therapy', EKB Journal Management System, 8(2), pp. 245-260. doi: 10.21608/aps.2024.291298.1173
Kamar, N., Michel, H., Seif el-Din, S., Lakkany, N., Elsherbiny, D. Non-alcoholic fatty liver disease: Insights into pathogenesis, molecular mechanisms, and therapy. EKB Journal Management System, 2024; 8(2): 245-260. doi: 10.21608/aps.2024.291298.1173

Non-alcoholic fatty liver disease: Insights into pathogenesis, molecular mechanisms, and therapy

Archives of Pharmaceutical Sciences Ain Shams University
Article 4, Volume 8, Issue 2, December 2024, Page 245-260  XML PDF (391.32 K)
Document Type: Review Article
DOI: 10.21608/aps.2024.291298.1173
View on SCiNiTO View on SCiNiTO
Authors
Nourhan M. Kamar email 1; Haidy E. Michelorcid 2; Sayed H. Seif el-Din1; Naglaa M. Lakkany1; Doaa A. Elsherbinyorcid 2
1Department of Pharmacology, Theodor Bilharz Research Institute, 12411, Giza, Egypt
2Department of Pharmacology and Toxicology, Faculty of Pharmacy, Ain Shams University, Cairo, 11566, Egypt
Abstract
Abstract
Nonalcoholic fatty liver disease (NAFLD) is a chronic liver disease prevalent worldwide, which affects patients' quality of life, and has become a significant health and economic issue. NAFLD has been classified into nonalcoholic fatty liver (NAFL) and nonalcoholic steatohepatitis (NASH). Understanding how biochemical pathways affect illness development and progression on an individual level is critical for effective care. In this review, the current understandings of the risk factors affecting the progression of NAFLD are summarized. Moreover, the review highlights the multifaceted pathogenesis of NAFLD, in addition to the molecular mechanisms that promote to the advancement and progression of NAFLD for example lipotoxicity, insulin resistance, proinflammatory cytokines and inflammation, oxidative damage and mitochondrial malfunction, additionally, gut microbiota and bacterial dysbiosis. In addition, this review highlights lifestyle adjustments, and therapeutics with favorable prospects used for the management of NAFLD. Medicinal treatments used for their potential benefits, such as drugs targeting gut microbiota, as well as lipid lowering drugs are discussed.
Keywords
Non-alcoholic Steatohepatitis; High-Fat Diet; Fibrosis; Pathogenesis; Management
Statistics
Article View: 145
PDF Download: 107